08:40 AM EDT, 06/26/2025 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Thursday that its Zoryve cream 0.15% received a "strong recommendation" from the American Academy of Dermatology for the management of adult atopic dermatitis.

The recommendation, in an AAD focused update paper, mentions Zoryve's ability to deliver clinically meaningful improvements in pruritus and disease severity as a non-steroid option for daily disease management, the company said.